Last close As at 05/08/2026
EUR0.77
▲ −0.03 (−3.75%)
Market capitalisation
—
Research: TMT
1Spatial’s trading update confirms FY20 (ended January) financials will be in line with our estimates. We update exceptionals, amortisation of acquired intangibles and the year-end cash balance but make no material changes to underlying forecasts. The company has seen no impact from COVID-19 so far but is ready to take ‘appropriate action’. Given this, the halving of the share price in the last two weeks seems an overreaction.
Written by
1Spatial |
Trading in line, no COVID-19 impact so far |
Trading update |
Software & comp services |
23 March 2020 |
Share price performance
Business description
Next events
Analysts
1Spatial is a research client of Edison Investment Research Limited |
|||||||||||||||||||||||||||||||||||||||||||||||||
1Spatial’s trading update confirms FY20 (ended January) financials will be in line with our estimates. We update exceptionals, amortisation of acquired intangibles and the year-end cash balance but make no material changes to underlying forecasts. The company has seen no impact from COVID-19 so far but is ready to take ‘appropriate action’. Given this, the halving of the share price in the last two weeks seems an overreaction.
Year end |
Revenue (£m) |
Adjusted EBITDA* (£m) |
EBIT* |
EPS* |
EV/sales |
EV/EBIT* |
P/E |
01/18 |
16.9 |
0.4 |
(1.3) |
(2.3) |
0.7 |
N/A |
N/A |
01/19 |
17.6 |
1.2 |
(0.7) |
(1.1) |
0.6 |
N/A |
N/A |
01/20e |
23.0 |
3.1 |
0.8 |
0.8 |
0.5 |
13.3 |
17.7 |
01/21e |
25.6 |
3.7 |
1.5 |
1.0 |
0.4 |
7.6 |
13.2 |
Note: *Adjusted EBITDA, EBIT and EPS (fully diluted) are normalised, excluding amortisation of acquired intangibles, exceptional items and share-based payments. Forecasts include the consolidation of Geomap-Imagis from May 2019.
Revenue/EBITDA at least £23m and £3m
Expectations for revenue and EBITDA of ‘at least’ £23m and £3m are in line with our forecasts. The year-end gross cash balance of £5.1m is below our estimate (£6.1m), reflecting delays in cash collection. We understand collections picked up in February and, excluding a £1.0m exceptional charge related to the Geomap-Imagis (GI) acquisition, 1Spatial generated £1.5m of cash in H2.
Underlying forecasts unchanged despite COVID-19
We adjust our forecasts to include the amortisation of acquired intangibles for the first time (£0.8m, non-cash), increase FY20 exceptionals to £1.0m (previously £0.5m) and reduce our year-end FY20 gross cash balance (see Exhibit 1). However, our underlying forecasts are unchanged. 1Spatial has seen no impact on orders from COVID-19 so far but stands ready to take ‘appropriate action’.
Progress in FY20 and prospects undimmed
1Spatial made substantial progress in FY20 in our view. The GI deal addressed a geography unaligned strategically and underperforming financially (see Fixing France). The business reached underlying EBIT breakeven and was cash generative in H2. Clearly COVID-19 increases forecast uncertainty, but there is no direct impact on 1Spatial so far. The US is growing healthily and the 1Data Gateway launch should significantly enhance scalability.
Valuation: Share price halved, forecasts unchanged
1Spatial’s share price has halved in two weeks. At 13.5p, it stands at its lowest level since listing and the implied FY21e EV/EBIT multiple is just 7.6x. It is difficult to rule out an indirect impact of COVID-19 on the business but 1Spatial appears willing, and has scope, to mitigate an impact should it be needed. In our view, the current rating is not appropriate for a growing, now cash-generative business that has executed well in the last three years.
Forecast changes
Exhibit 1: Forecast changes
£m |
FY19 |
FY20e |
FY21e |
||||
Old |
New |
Change (%) |
Old |
New |
Change (%) |
||
Revenue |
17.6 |
22.8 |
23.0 |
0.9 |
25.6 |
25.6 |
0.0 |
EBITDA |
1.2 |
3.1 |
3.1 |
0.0 |
3.7 |
3.7 |
0.0 |
Depreciation |
(0.1) |
(0.1) |
(0.2) |
(0.2) |
(0.2) |
||
IFRS-16 |
0.0 |
(0.0) |
(1.0) |
(0.0) |
(0.9) |
||
Amortisation of cap soft |
(1.8) |
(2.2) |
(1.2) |
(2.1) |
(1.2) |
||
Adjusted EBIT |
(0.7) |
0.8 |
0.8 |
0.0 |
1.5 |
1.5 |
0.0 |
Amortisation of acquired intangibles |
0.0 |
0.0 |
(0.8) |
0.0 |
(1.2) |
||
Exceptionals |
(0.7) |
(0.5) |
(1.0) |
0.0 |
0.0 |
||
Reported EBIT |
(1.4) |
0.3 |
(1.0) |
N/A |
1.5 |
0.3 |
(78.3) |
Gross cash |
6.4 |
6.1 |
5.1 |
(16.1) |
6.9 |
6.8 |
(0.4) |
Debt |
0.0 |
(0.8) |
(1.2) |
(0.8) |
(1.2) |
||
Net cash |
6.4 |
5.3 |
3.9 |
(26.7) |
6.1 |
5.6 |
(7.6) |
Source: 1Spatial announcements, Edison Investment Research
Exhibit 2: Financial summary
£000s |
2016 |
2017 |
2018 |
2019 |
2020e |
2021e |
||
Year end 31 January |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
IFRS |
||
PROFIT & LOSS |
||||||||
Revenue |
|
|
18,300 |
15,133 |
16,938 |
17,624 |
23,036 |
25,638 |
Delivery costs |
(7,715) |
(6,868) |
(7,994) |
(8,449) |
(10,953) |
(12,325) |
||
Gross Profit |
10,585 |
8,265 |
8,944 |
9,175 |
12,083 |
13,313 |
||
Adjusted EBITDA |
|
|
2,902 |
(874) |
403 |
1,188 |
3,135 |
3,730 |
Operating Profit (before amort. and except.) |
|
|
1,584 |
(12,494) |
(1,302) |
(738) |
836 |
1,471 |
Acquired Intangible Amortisation |
(200) |
0 |
0 |
0 |
(800) |
(1,150) |
||
Exceptionals |
(1,081) |
(2,590) |
(1,041) |
(672) |
(1,000) |
0 |
||
Share based payments |
(976) |
(566) |
538 |
(218) |
(218) |
(218) |
||
Operating Profit |
(673) |
(15,650) |
(1,805) |
(1,628) |
(1,182) |
103 |
||
Net Interest |
(27) |
(25) |
(151) |
(191) |
(36) |
(102) |
||
Other |
(421) |
(266) |
0 |
0 |
0 |
0 |
||
Profit Before Tax (norm) |
|
|
1,136 |
(12,785) |
(1,453) |
(929) |
799 |
1,367 |
Profit Before Tax (FRS 3) |
|
|
(1,121) |
(15,941) |
(1,956) |
(1,819) |
(1,218) |
0 |
Tax |
503 |
1,081 |
753 |
389 |
150 |
150 |
||
Profit After Tax (norm) |
1,136 |
(12,785) |
(1,453) |
(929) |
799 |
1,139 |
||
Profit After Tax (FRS 3) |
(618) |
(14,860) |
(1,203) |
(1,430) |
(1,068) |
150 |
||
Average Number of Shares Outstanding (m) |
691.3 |
728.9 |
63.3 |
87.4 |
104.9 |
111.2 |
||
EPS - normalised (p) |
|
|
0.16 |
(1.75) |
(2.30) |
(1.06) |
0.76 |
1.02 |
EPS - normalised fully diluted (p) |
|
|
0.16 |
(1.75) |
(2.30) |
(1.06) |
0.76 |
1.02 |
EPS - (IFRS) (p) |
|
|
(0.09) |
(2.04) |
(1.90) |
(1.64) |
(1.02) |
0.14 |
Dividend per share (p) |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
||
Gross Margin (%) |
57.8 |
54.6 |
52.8 |
52.1 |
52.5 |
51.9 |
||
EBITDA Margin (%) |
15.9 |
N/A |
2.4 |
6.7 |
13.6 |
14.5 |
||
Operating Margin (before GW and except.) (%) |
8.7 |
N/A |
N/A |
N/A |
3.6 |
5.7 |
||
BALANCE SHEET |
||||||||
Fixed Assets |
|
|
22,115 |
13,025 |
10,873 |
10,479 |
13,479 |
15,279 |
Intangible Assets |
18,900 |
11,968 |
10,540 |
10,194 |
13,194 |
14,994 |
||
Tangible Assets |
1,638 |
1,057 |
333 |
285 |
285 |
285 |
||
Investments |
1,577 |
0 |
0 |
0 |
0 |
0 |
||
Current Assets |
|
|
16,202 |
11,442 |
7,050 |
11,481 |
16,223 |
18,371 |
Stocks |
0 |
0 |
0 |
0 |
0 |
0 |
||
Debtors |
10,815 |
8,929 |
5,510 |
4,998 |
11,000 |
11,400 |
||
Cash |
4,996 |
1,966 |
1,319 |
6,358 |
5,098 |
6,846 |
||
Other |
391 |
547 |
221 |
125 |
125 |
125 |
||
Current Liabilities |
|
|
(11,071) |
(13,029) |
(10,234) |
(8,578) |
(13,204) |
(15,277) |
Creditors & other |
(11,071) |
(12,348) |
(9,183) |
(8,578) |
(12,004) |
(14,077) |
||
Short term borrowings |
0 |
(681) |
(1,051) |
0 |
(1,200) |
(1,200) |
||
Long Term Liabilities |
|
|
(1,579) |
(1,535) |
(899) |
(192) |
(192) |
(192) |
Long term borrowings |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other long-term liabilities |
(1,579) |
(1,535) |
(899) |
(192) |
(192) |
(192) |
||
Net Assets |
|
|
25,667 |
9,903 |
6,790 |
13,190 |
16,305 |
18,181 |
CASH FLOW |
||||||||
Operating Cash Flow |
|
|
(722) |
(1,061) |
245 |
(749) |
(1,477) |
5,300 |
Net Interest |
(31) |
(166) |
(167) |
(175) |
(36) |
(102) |
||
Tax |
55 |
425 |
751 |
410 |
150 |
150 |
||
Capex |
(3,800) |
(4,042) |
(1,035) |
(1,394) |
(3,297) |
(3,100) |
||
Acquisitions/disposals |
(1,033) |
(900) |
115 |
0 |
(4,500) |
(500) |
||
Financing |
1,940 |
896 |
0 |
7,996 |
5,500 |
0 |
||
Dividends |
0 |
0 |
0 |
0 |
0 |
0 |
||
Net Cash Flow |
(3,342) |
(4,848) |
(91) |
6,088 |
(2,460) |
1,748 |
||
Opening net debt/(cash) |
|
|
(8,250) |
(4,996) |
(604) |
(268) |
(6,358) |
(3,898) |
HP finance leases initiated |
0 |
0 |
0 |
0 |
0 |
0 |
||
Other |
88 |
456 |
(245) |
2 |
0 |
0 |
||
Closing net debt/(cash) |
|
|
(4,996) |
(604) |
(268) |
(6,358) |
(3,898) |
(5,646) |
Source: Company data, Edison Investment Research. Note: Forecasts include the acquisition of GI from May 2019.
|
|
Research: Healthcare
Hutchison China MediTech’s (HCM’s) investment case is focused on evolution into a global R&D and commercial-stage biopharma company with a marketed portfolio of innovation-led oncology drugs. 2020 is a golden year as HCM moves towards multiple domestic drug launches and is progressing key assets into registration studies globally. We expect surufatinib (NET) and savolitinib (exon 14 deletion NSCLC) China launches in 2020 and 2021, respectively, following in the footsteps of Elunate (third-line CRC), which is establishing its presence by its inclusion on the National Reimbursement Drug List. HCM is investing in its oncology commercial presence in China and its global clinical and regulatory capabilities (in the US, Europe and Japan). 2022 and 2023 should benefit from global drug launches providing continued pipeline progression. We value HCM at $5.9bn.